Our Pricing

Comparing Mounjaro Side Effects Hair Loss Options

Published on: June 03, 2026

Concerns about mounjaro side effects hair loss UK are common among patients considering tirzepatide treatment, though clinical trial data shows hair loss occurs in fewer than 5% of users [1]. At Cured Pharmacy, our UK-registered clinical team helps you understand the evidence behind this side effect and compare alternative weight loss treatments with different safety profiles.

Does Mounjaro Cause Hair Loss? Understanding the Clinical Evidence

Hair loss (telogen effluvium) has been reported in clinical trials of Mounjaro, though it remains a relatively uncommon side effect. In the landmark SURMOUNT-1 trial involving over 2,500 participants, hair loss was documented in approximately 3-5% of patients taking tirzepatide, compared to 1% in the placebo group [1]. This temporary shedding typically occurs 3-6 months after starting treatment and is often linked to rapid weight loss rather than the medication itself.

The mechanism behind weight loss-associated hair loss involves the body's stress response to significant caloric restriction and metabolic changes. When you lose weight rapidly — particularly more than 1kg per week — hair follicles can shift prematurely into the resting (telogen) phase, causing increased shedding [2]. This condition is usually self-limiting, with hair regrowth typically resuming within 6-9 months as the body adapts to its new metabolic state.

It's important to distinguish between medication-induced hair loss and nutritional deficiency-related thinning. Patients on Mounjaro may experience reduced nutrient absorption due to decreased food intake, potentially leading to deficiencies in iron, zinc, biotin, and protein — all essential for healthy hair growth [3]. Regular monitoring by your UK prescriber can help identify and address these deficiencies early.

Mounjaro Side Effects Hair Loss vs Wegovy and Other GLP-1 Treatments

When comparing hair loss rates across different weight loss injections, the evidence suggests similar incidence across the GLP-1 receptor agonist class. Wegovy (semaglutide) trials reported hair loss in approximately 3% of participants in the STEP programme, comparable to Mounjaro's profile [4]. Saxenda (liraglutide), which requires daily injections, showed similar rates in long-term studies, suggesting the side effect correlates more with the degree of weight loss than the specific medication used.

The key differentiator between these treatments isn't hair loss risk, but rather the speed and magnitude of weight loss achieved. Mounjaro's dual GIP/GLP-1 mechanism produces more significant weight reduction — averaging 22.5% body weight loss at the highest dose over 72 weeks in SURPASS-3 [1] — which may theoretically increase the likelihood of telogen effluvium in susceptible individuals. Wegovy achieved an average 14.9% weight loss in the STEP-1 trial, whilst Saxenda typically produces 5-10% reduction [4][5].

For patients particularly concerned about hair thinning, slower-acting treatments like Orlistat may present an alternative, though with significantly lower efficacy. Orlistat works by blocking fat absorption rather than suppressing appetite, producing more gradual weight loss that rarely triggers telogen effluvium [6].

Which Treatment Has the Lowest Hair Loss Risk?

Non-injectable options like Orlistat and Xenical have the lowest reported incidence of hair loss, primarily because they produce slower, more modest weight reduction. However, clinical trials show these medications achieve only 5-10% body weight loss compared to 15-22% with GLP-1 treatments [6]. Your UK prescriber will help balance efficacy expectations against side effect concerns based on your individual health profile and weight loss goals.

Managing and Preventing Hair Loss During Mounjaro Treatment

If you experience hair thinning whilst taking Mounjaro, several evidence-based strategies can help minimise shedding and support regrowth. First, ensure adequate protein intake — aim for 1.2-1.5g per kilogram of body weight daily, as protein deficiency is a primary driver of telogen effluvium during weight loss [3]. Many patients on GLP-1 treatments struggle to meet protein targets due to reduced appetite, making supplementation with protein shakes or powders particularly valuable.

Micronutrient optimisation is equally critical. Request blood tests from your UK prescriber to check ferritin (iron stores), vitamin D, zinc, and B vitamins, all of which play essential roles in hair follicle health. Ferritin levels below 40 ng/mL are associated with increased hair shedding even in the absence of clinical anaemia [7]. Supplementation should be guided by blood results rather than taken empirically, as excessive intake of certain nutrients can paradoxically worsen hair loss.

Consider slowing your rate of weight loss if hair shedding becomes significant. Whilst Mounjaro is typically titrated upward every four weeks, your prescriber may recommend maintaining a lower dose for longer to achieve more gradual reduction. This approach can reduce metabolic stress on hair follicles whilst still providing meaningful weight loss benefits. Most importantly, remember that telogen effluvium is temporary — hair regrowth typically resumes once your weight stabilises, even if you continue the medication.

When to Seek Medical Advice About Hair Loss

Contact your UK prescriber if you experience sudden, severe hair loss (more than 100-150 hairs daily), patchy bald spots, or scalp symptoms like itching or scaling, as these may indicate conditions unrelated to Mounjaro. Persistent hair thinning beyond 9-12 months should also be evaluated to rule out underlying thyroid disorders or autoimmune conditions that can be unmasked by weight loss.

Alternative Weight Loss Treatments for Hair Loss-Prone Patients

For patients with a history of hair loss disorders or significant concern about thinning, several alternative approaches merit consideration. Orlistat-based treatments (including Xenical, Alli, and generic Orlistat) work through fat malabsorption rather than appetite suppression, producing weight loss of approximately 5-10% over 6-12 months [6]. Because the reduction occurs more gradually, telogen effluvium is rarely triggered. These medications are available at competitive UK pricing and require clinical assessment by a UK prescriber.

Another option is to combine a lower dose of GLP-1 treatment with lifestyle modifications to achieve slower weight loss. Starting Mounjaro at 2.5mg and maintaining this dose for extended periods, rather than titrating to maximum strength, can provide appetite control benefits whilst minimising the metabolic stress associated with rapid reduction. This approach requires patience but may be preferable for individuals prioritising hair preservation.

Some patients benefit from a phased approach: using Orlistat for initial weight loss, then transitioning to a GLP-1 treatment once they're within 10-15% of their goal weight. This strategy front-loads the period of rapid loss when hair shedding risk is highest with a medication less likely to trigger it, whilst still accessing the superior maintenance benefits of treatments like Mounjaro or Wegovy.

The Science Behind Weight Loss and Hair Growth Cycles

Understanding the hair growth cycle helps contextualise why weight loss treatments can trigger temporary shedding. Human hair follicles cycle through three phases: anagen (active growth, lasting 2-7 years), catagen (transition, 2-3 weeks), and telogen (resting, 2-4 months) [2]. Normally, 85-90% of scalp hairs are in anagen at any time, with only 10-15% in telogen. When the body experiences significant metabolic stress — whether from rapid weight loss, illness, or major surgery — a higher proportion of follicles shift prematurely into telogen.

This phenomenon, termed telogen effluvium, manifests as increased shedding approximately 3 months after the triggering event, which is the time required for resting hairs to complete their cycle and fall out [2]. The delay often confuses patients, who may not connect hair loss occurring in month 4 of Mounjaro treatment with the rapid weight loss they experienced in month 1. Crucially, the follicles themselves remain healthy and capable of producing new hair once the metabolic stress resolves.

Research indicates that weight loss velocity is the strongest predictor of telogen effluvium risk. Studies show that losing more than 1kg per week significantly increases the likelihood of noticeable shedding, whilst rates below 0.5kg weekly rarely trigger the condition [3]. This explains why Mounjaro, which can produce 1-2kg weekly loss in the initial months, shows higher hair loss reporting than slower-acting alternatives.

How Long Does Hair Loss Last on Mounjaro?

Most patients who experience telogen effluvium on Mounjaro notice shedding beginning 2-4 months after starting treatment, peaking around months 4-6, then gradually improving over the following 3-6 months [2]. Total recovery to pre-treatment hair density typically occurs within 9-12 months, though this varies based on individual factors including nutritional status, genetics, and whether weight loss continues or stabilises.

Getting Started with Weight Loss Treatment at Cured Pharmacy

At Cured Pharmacy, we offer transparent access to all major weight loss treatments, with prices displayed upfront before your free clinical consultation. Mounjaro is available from £124.99, dispensed only after assessment by our UK-registered prescribers who evaluate your medical history, current medications, and suitability for treatment. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), oversees all clinical services to ensure the highest standards of pharmaceutical care.

Your online consultation takes under 3 minutes and covers essential health screening including cardiovascular history, current BMI, previous weight loss attempts, and any concerns about side effects like hair loss. Our prescribers can recommend the most appropriate treatment based on your individual risk profile and goals, whether that's Mounjaro, Wegovy, Saxenda, or an Orlistat-based option. All consultations are conducted by UK-registered clinicians, and all medications dispensed are genuine UK-licensed products.

We provide discreet packaging and competitive delivery options across the UK, with ongoing support from our pharmacy team throughout your treatment journey. If you experience side effects including hair thinning, our clinical team is available to adjust your treatment plan, recommend appropriate monitoring, or switch you to an alternative option. Starting your assessment takes just minutes — select your preferred treatment and complete the online consultation to receive a personalised recommendation from a UK prescriber.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Harrison, S., & Bergfeld, W. (2009). Diffuse Hair Loss: Its Triggers and Management. Cleveland Clinic Journal of Medicine, 76(6), 361–367. https://doi.org/10.3949/ccjm.76a.08080 [accessed 13 August 2026]
3. Guo, E. L., & Katta, R. (2017). Diet and Hair Loss: Effects of Nutrient Deficiency and Supplement Use. Dermatology Practical & Conceptual, 7(1), 1–10. https://doi.org/10.5826/dpc.0701a01 [accessed 13 August 2026]
4. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
5. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
6. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
7. Rushton, D. H. (2002). Nutritional Factors and Hair Loss. Clinical and Experimental Dermatology, 27(5), 396–404. https://doi.org/10.1046/j.1365-2230.2002.01076.x [accessed 13 August 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Hair loss can have multiple causes, and persistent or severe symptoms should be evaluated by a healthcare professional to rule out underlying medical conditions.